Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)


Crinetics announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist.

Crinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly


Crinetics Pharmaceuticals presents new data from its clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly.

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs


Crinetics announces the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs.

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts


Crinetics announces that the late-breaking abstracts accepted for presentation at ENDO 2024 were released earlier than the previously announced embargoed date.

Crinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees.